title: [The preventive treatment of stroke in patients with discirculatory encephalopathy with a depressive syndrome].
abstract: We studied the clinical efficacy of cytoflavin in 30 patients (group 1) with I and II stages of discirculatory encephalopathy (DE) and a depressive syndrome associated with arterial hypertension. Cytoflavin was added to standard treatment intravenously in drops in dose 10 ml per 200 ml of 0,9% NaCl during 10 days and then in dose 2 tablets twice a day during 25 days. The control group (n=29 patients) received placebo. The treatment duration was 35 days but patients were followed up for 90 days with control visits at 5, 10, 20-35 and 65-90 days of treatment. After the treatment, there was the reduction of neurological symptoms and subjective disorders in patients of group 1. The improvement of attention concentration, reasoning and speech activity as well as the gradual restoration of memory were noted at 20-35 days. The positive impact of cytoflavin on depression was dependent on its severity. The effect was higher in mild depression, also, the treatment decreased the severity of depression from "moderate" or "severe' to "mild". Cytoflavin may be recommended for patients with DE and a depressive syndrome associated with arterial hypertension as a preventive medication from the progression of cerebrovascular pathology and development of stroke.
authors.forename: S K
authors.initials: SK
authors.lastname: Erkebaeva
authors.forename: E S
authors.initials: ES
authors.lastname: Nurguzhaev
authors.forename: B G
authors.initials: BG
authors.lastname: Gafurov
authors.forename: G U
authors.initials: GU
authors.lastname: Tuksanbaeva
mesh_terms: D002561:Cerebrovascular Disorders / Q000150:complications*; D003866:Depressive Disorder / Q000209:etiology*; D004338:Drug Combinations; D005260:Female; D005486:Flavin Mononucleotide / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications*; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009536:Niacinamide / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D020521:Stroke / Q000209:etiology* / Q000517:prevention & control*; D013386:Succinates / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D018696:Neuroprotective Agents; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate